Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma

L. Di Lauro, C. Nunziata, M. G. Arena, P. Foggi, I. Sperduti, M. Lopez

Research output: Contribution to journalArticlepeer-review


This phase II study was designed to evaluate the activity and safety of a combination of irinotecan, docetaxel and oxaliplatin in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Forty patients with measurable distant metastasis received irinotecan 150 mg m-2 and docetaxel 60 mg m-2 on day 1, and oxaliplatin 85 mg m-2 on day 2. Cycles were repeated every 3 weeks. The primary end point was to demonstrate a 50% improvement in time-to-progression (TTP) over historical controls. All patients were evaluable. Median TTP was 6.5 months (95% confidence interval (CI) 5.6-7.4), the overall response rate was 50% (95% CI 35-65%) and the median overall survival was 11.5 months (95% CI 8.7-14.3). Grade 3/4 neutropaenia occurred in 47.5% of patients. There were four episodes of febrile neutropaenia in three patients. Other non-haematological grade 3 toxicities included diarrhoea in four patients (10%), vomiting in three patients (7.5%) and mucositis in two patients (5%). The irinotecan, docetaxel and oxaliplatin combination chemotherapy is an active and well-tolerated novel regimen for treating metastatic gastric or GEJ adenocarcinoma and deserves further evaluation in randomised trials and in combination with molecular targeting agents.

Original languageEnglish
Pages (from-to)593-597
Number of pages5
JournalBritish Journal of Cancer
Issue number5
Publication statusPublished - Aug 28 2007


  • Docetaxel
  • Irinotecan
  • Metastatic gastric cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma'. Together they form a unique fingerprint.

Cite this